

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

INA-6

RRID:CVCL_5209

Type: Cell Line

Proper Citation

RRID:CVCL_5209

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5209

Proper Citation: RRID:CVCL_5209

Description: Cell line INA-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:10936422](#), [PMID:11920233](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:19621390](#), [PMID:22806891](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Characteristics: IL6 dependent., Characteristics: Produces Ig kappa., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: INA-6

Synonyms: INA6

Cross References: BTO:BTO_0004745, EFO:EFO_0005386, BioSample:SAMN10989605, cancercellines:CVCL_5209, Cell_Model_Passport:SIDM01555, Cosmic:1424216, Cosmic:1483075, Cosmic:2081383, DepMap:ACH-000512, DSMZ:ACC-862, DSMZCellDive:ACC-862, Wikidata:Q54897699

ID: CVCL_5209

Record Creation Time: 20220427T220636+0000

Ratings and Alerts

No rating or validation information has been found for INA-6.

No alerts have been found for INA-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. Molecular cancer therapeutics, 25(6), 1016.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Kuric M, et al. (2024) Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics. Cancer research communications, 4(4), 1150.

Aass KR, et al. (2022) Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells. iScience, 25(1), 103605.